Can adherence to antihypertensive therapy be used to promote adherence to statin therapy?
Richard H Chapman1, Elise M Pelletier1, Paula J Smith1, Craig S Roberts2
1US Health Economics and Outcomes Research, IMS Health, Falls Church, VA, USA; 2Global Outcomes Research, Pfizer Inc, New York, NY, USA
Objective: To compare adherence with statin therapy in patients switching to single-pill amlodipine besylate/atorvastatin calcium with patients adding a separate statin to their amlodipine regimen.
Methods: We identified hypertensive patients prescribed amlodipine who switched to amlodipine/atorvastatin (switch) or added a statin to their amlodipine regimen (add-on) from July 2004 to June 2007. Propensity score matching (1 switch:3 add-on) was applied based on ‘nearest neighbor’ approach. The primary adherence measure was patients with proportion of days covered (PDC) ≥0.80 at 180 days; secondary measures included mean PDC and persistence. A sensitivity analysis was performed, accounting for total statin/amlodipine exposure.
Results: Among 4556 matched patients (n = 1139 switch; n = 3417 add-on), mean age was 53.9 years and 52.1% were male. After 180 days, adherence with statin therapy was higher for the switch vs add-on cohort (50.8% vs 44.3%; P < 0.001). After adjusting for pre-index amlodipine adherence, the switch cohort was more likely to be adherent than the add-on cohort (odds ratio: 1.64 [95% confidence interval: 1.42 to 1.89]). Persistence was higher in the switch than the add-on cohort (127.6 vs 117 days; P < 0.001).
Conclusion: Hypertensive patients taking amlodipine who initiated statin therapy via single-pill amlodipine/atorvastatin were more likely to remain adherent to their statin than patients adding a separate statin to their antihypertensive regimen.
Keywords: adherence, amlodipine, atorvastatin, cardiovascular disease, persistence, single-pill
This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php
Readers of this article also read:
Comparison with ancestral diets suggests dense acellular carbohydrates promote an inflammatory microbiota, and may be the primary dietary cause of leptin resistance and obesity
Published Date: 6 July 2012
Chitosan–Pluronic nanoparticles as oral delivery of anticancer gemcitabine: preparation and in vitro study
Hosseinzadeh H, Atyabi F, Dinarvand R, Ostad SN
Published Date: 11 April 2012
Cavallari LH, Jeong H, Bress A
Published Date: 7 November 2011
Chauhan A, Zubair S, Tufail S, Sherwani A, Sajid M, Raman SC, Azam A, Owais M
Published Date: 12 October 2011
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Noreddin AM, Elkhatib WF, Cunnion KM, Zhanel GG
Published Date: 7 October 2011
Comparison of two treatments for coxarthrosis: local hyperthermia versus radio electric asymmetrical brain stimulation
Castagna A, Rinaldi S, Fontani V, Mannu P, Lotti Margotti M
Published Date: 25 July 2011
Joy C Coleman, Colleen T Downs
Published Date: 10 September 2010
Morgellons disease: Analysis of a population with clinically confirmed microscopic subcutaneous fibers of unknown etiology
Virginia R Savely, Raphael B Stricker
Published Date: 13 May 2010
Classification of heterodimer interfaces using docking models and construction of scoring functions for the complex structure prediction
Yuko Tsuchiya, Eiji Kanamori, Haruki Nakamura, et al
Published Date: 22 September 2009
Lily Koo Lin, Han Lee, Eli Chang
Published Date: 6 October 2008